Combined Shareholders’ Meeting of IPSEN S.A. Held on 30 May 2018
The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was held today, in the presence of the members of the Board of Directors and the Group’s Executive Management team.
The Shareholders’ Meeting approved all the resolutions submitted by the Board of Directors and in particular, the distribution of a dividend of €1.00 per share to be paid on 6 June 2018 (ex-dividend date 4 June 2018).
The Shareholders’ Meeting also approved the renewal of Ms. Anne Beaufour as a director, as well as the appointments as directors of M. Philippe Bonhomme, to replace MAYROY S.A., and of M. Paul Sekhri and M. Piet Wigerinck. The Board welcomed the newly-appointed directors.
Ms. Hélène Auriol-Potier, M. Hervé Couffin and M. Pierre Martinet did not wish to renew their mandate. The Board also noted today the resignation of M. Christophe Verot, as a director. The Board thanked them for their major contributions to the Board of Directors.
Following the Shareholders’ Meeting, the new Board of Directors is comprised of 12 members, five of whom are women.
During the Meeting, David Meek, Chief Executive Officer and Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer, focused on the group strategy, highlights and financial results for 2017, and also confirmed the objectives and guidance for 2018.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com
Vice President, Corporate External Communications
+44 (0) 1753 627733
Vice President, Investor Relations
+44 (0) 1753 627721
Brigitte Le Guennec
Senior Manager, Global External Communications
+33 (0)1 58 33 51 17
Investor Relations Manager
+33 (0)1 58 33 51 04
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
TX-SAILPOINT22.8.2018 07:03 | pressemeddelelse
SailPoint’s IdentityIQ Tames the Tsunami of Bots, Apps and Cloud Infrastructures
TX-SCHLUMBERGER21.8.2018 19:07 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results Conference Call
WA-AMAZON.COM21.8.2018 17:02 | pressemeddelelse
Amazon Game Studios Announces The Grand Tour Game
CA-ANDERSEN-TAX21.8.2018 15:32 | pressemeddelelse
Andersen Global Expands in Africa with Oliveira & Associados
TX-MAVENIR21.8.2018 15:02 | pressemeddelelse
Mavenir Introduces RCS Business Messaging Partner Program to Enable MNO’s A2P Revenue Growth
DYNACOR-GOLD-MINES21.8.2018 14:05 | pressemeddelelse
Dynacor Announces First Quarterly Dividend Payment
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum